Osteoporosis – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Osteoporosis – Pipeline Review, H2 2019’, provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Osteoporosis

– The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects

– The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteoporosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteoporosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abreos Biosciences Inc

Addpharma Inc

Aerami Therapeutics

Affilogic SAS

AgeX Therapeutics Inc

AlphaMab Co Ltd

Altum Pharmaceuticals Inc

Amgen Inc

Aryogen Pharmed Co

Axsome Therapeutics Inc

Bainan Biotech ApS

BIOCND Inc

Biosion Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Cellatoz Therapeutics Inc

ChoDang Pharm Co Ltd

Chugai Pharmaceutical Co Ltd

Citragen Pharmaceuticals Inc

Corium International Inc

CSPC Pharmaceutical Group Ltd

Daewoong Pharmaceutical Co Ltd

Dong Wha Pharma Co Ltd

Eli Lilly and Co

EndoCeutics Inc

Enesi Pharma Ltd

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Evgen Pharma Plc

Genor BioPharma Co Ltd

GlycoNex Inc

GPN Therapeutics Inc

Haoma Medica Ltd

Helixmith Co Ltd

Histide AG

HNB Therapeutics LLC

Huons Co Ltd

Huons Global Co Ltd

IMGENEX India Pvt Ltd

Immunwork Inc

InnoPharmaScreen Inc

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Ipsen SA

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Kolmar Pharma Co Ltd

Kyoto Pharmaceutical Industries Ltd

LBL Biotech Corp

Lead Discovery Center GmbH

Lupin Ltd

Luye Pharma Group Ltd

Max Biopharma Inc

Merck & Co Inc

Mesentech Inc

Metabolab Inc

Millendo Therapeutics Inc

Nano Intelligent Biomedical Engineering Corp

Nanomedic Inc

NeuClone Pty Ltd

NovMetaPharma Co Ltd

Omeros Corp

Ortho Regenics Pvt Ltd

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

PhytoHealth Corp

Qilu Pharmaceutical Co Ltd

R Pharm

Regenerative Arthritis & Bone Medicine Inc

Reliance Life Sciences Pvt Ltd

Ribomic Inc

Sandoz International GmbH

Shandong Danhong Pharmaceutical Co Ltd

Shanghai Biomabs Pharmaceuticals Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong Pharm Co Ltd

Stelis Biopharma Pvt Ltd

Suzhou Stainwei Biotech Inc

Taithera Inc

Terpenoid Therapeutics Inc

The National Institute for Biotechnology in the Negev Ltd

Tritech Biopharmaceuticals Co Ltd

TSH Biopharm Corporation Ltd

Uni-Bio Science Group Ltd

USV Pvt Ltd

Vibe Pharmaceuticals LLC

Vidasym Inc

Viking Therapeutics Inc

Wroclawskie Centrum Badan EIT+ Sp z oo

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Osteoporosis Overview 7

Osteoporosis Therapeutics Development 8

Osteoporosis Therapeutics Assessment 25

Osteoporosis Companies Involved in Therapeutics Development 35

Osteoporosis Drug Profiles 66

Osteoporosis Dormant Projects 239

Osteoporosis Discontinued Products 247

Osteoporosis Product Development Milestones 249

Appendix 258

List of Tables

List of Tables

Number of Products under Development for Osteoporosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Osteoporosis – Pipeline by Abreos Biosciences Inc, H2 2019

Osteoporosis – Pipeline by Addpharma Inc, H2 2019

Osteoporosis – Pipeline by Aerami Therapeutics, H2 2019

Osteoporosis – Pipeline by Affilogic SAS, H2 2019

Osteoporosis – Pipeline by AgeX Therapeutics Inc, H2 2019

Osteoporosis – Pipeline by AlphaMab Co Ltd, H2 2019

Osteoporosis – Pipeline by Altum Pharmaceuticals Inc, H2 2019

Osteoporosis – Pipeline by Amgen Inc, H2 2019

Osteoporosis – Pipeline by Aryogen Pharmed Co, H2 2019

Osteoporosis – Pipeline by Axsome Therapeutics Inc, H2 2019

Osteoporosis – Pipeline by Bainan Biotech ApS, H2 2019

Osteoporosis – Pipeline by BIOCND Inc, H2 2019

Osteoporosis – Pipeline by Biosion Inc, H2 2019

Osteoporosis – Pipeline by Bone Biologics Corp, H2 2019

Osteoporosis – Pipeline by Bristol-Myers Squibb Co, H2 2019

Osteoporosis – Dormant Projects, H2 2019

Osteoporosis – Discontinued Products, H2 2019

Osteoporosis – Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures

List of Figures

Number of Products under Development for Osteoporosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports